风湿科医生对早期RA初始甲氨蝶呤联合治疗信念的量化研究
该研究采用贝叶斯信念启发法,让40名风湿科医生分配筹码以量化其对早期中重度RA患者6个月内ACR50应答概率的信念。汇总分析显示,医生认为三联治疗优于MTX单药(RR 1.97;95%CI 1.35-2.89)和双联治疗(RR 1.32;95%CI 1.03-1.73),但存在悲观与乐观亚组,信念差异可能部分解释三联治疗使用的变异性。
要点
- 汇总分析中医生认为三联治疗优于MTX单药(RR 1.97)和双联治疗(RR 1.32)。
- 悲观亚组(n=10)认为各治疗相似,乐观亚组(n=10)认为三联治疗最优(RR 4.03)。
- 若三联治疗真优于MTX,需100例试验说服悲观者;若无中等效应,需475例非劣效试验说服乐观者。
核心结论
- 风湿科医生对三联治疗有效性的信念存在差异,可能部分解释其使用差异。
- 由于信念强度,部分医生即使面对新证据也可能不愿改变。
研究设计与样本
- 贝叶斯信念启发法,40名风湿科医生分配20个筹码(每个代表5%信念权重)于MTX(口服和皮下)、MTX+HCQ双联和三联治疗。
- 拟合参数分布,计算成对中位相对风险(RR)及95%可信区间,并估算新试验所需样本量。
主要发现
- 汇总分析中,三联治疗 perceived 优于MTX(RR 1.97;95%CI 1.35-2.89)和双联治疗(RR 1.32;95%CI 1.03-1.73)。
- 悲观亚组(n=10)认为所有治疗相似;乐观亚组(n=10)认为三联治疗最有效(RR 4.03;95%CI 2.22-10.12)。
- 口服与皮下MTX比较也见类似变异性。
关键数值与推荐
- 三联治疗 vs MTX:RR 1.97(95%CI 1.35-2.89)。
- 三联治疗 vs 双联治疗:RR 1.32(95%CI 1.03-1.73)。
- 乐观亚组中三联治疗 vs 其他:RR 4.03(95%CI 2.22-10.12)。
- 假设三联治疗真优于MTX,需100例试验说服悲观者;若三联治疗真无中等效应(RR<1.5),需475例非劣效试验说服乐观者。
临床怎么用
- 临床医生应意识到自身对三联治疗有效性的信念可能影响治疗选择。
- 面对新证据时,信念强度可能导致部分医生不愿改变实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To quantify rheumatologists' beliefs about the effectiveness of triple therapy (MTX + HCQ + SSZ) and other commonly used initial treatments for RA. METHODS: In a Bayesian belief elicitation exercise, 40 rheumatologists distributed 20 chips, each representing 5% of their total weight of belief on the probability that a typical patient with moderate-severe early RA would have an ACR50 response within 6 months with MTX (oral and s.c.), MTX + HCQ (dual therapy) and triple therapy. Parametric distributions were fit, and used to calculate pairwise median relative risks (RR), with 95% credible intervals, and estimate sample sizes for new trials to shift these beliefs. RESULTS: In the pooled analysis, triple therapy was perceived to be superior to MTX (RR 1.97; 1.35, 2.89) and dual therapy (RR 1.32; 1.03, 1.73). A pessimistic subgroup (n = 10) perceived all treatments to be similar, whereas an optimistic subgroup (n = 10) believed triple therapy to be most effective of all (RR 4.03; 2.22, 10.12). Similar variability was seen for the comparison between oral and s.c. MTX. Assuming triple therapy is truly more effective than MTX, a trial of 100 patients would be required to convince the pessimists; if triple therapy truly has no-modest effect (RR <1.5), a non-inferiority trial of 475 patients would be required to convince the optimists. CONCLUSION: Rheumatologists' beliefs regarding the effectiveness of triple therapy vary, which may partially explain the variability in its use. Owing to the strength of beliefs, some may be reluctant to shift, even with new evidence.
引用
- Pokharel G, Deardon R, Johnson SR, et al. Effectiveness of initial methotrexate-based treatment approaches in early rheumatoid arthritis: an elicitation of rheumatologists' beliefs. Rheumatology (Oxford). 2021. PMID: 33367919. doi:10.1093/rheumatology/keaa803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。